Why is Prostate Cancer on the Rise Among Younger Men? Dr. Manish Singhal скачать в хорошем качестве

Why is Prostate Cancer on the Rise Among Younger Men? Dr. Manish Singhal

Prostate cancer is usually a disease of elderly people The median age is between 65 to 75 years #drmanishsinghal #prosatecancer #cancerdoctor #healthylifestyle #oncologist #cancertreatment We see Prostate Cancer as an increasing problem in young men under the age of 50 or less than 50 That the sperms can survive for 2-3 days in the female's genital tract. This secondary sexual organ starts growing from the time of puberty. The action of testosterone, the male hormone, it gradually increases its size. Benign Prostatic Hypertrophy is a very common disease found in Elderly People.which reduces the flow of urine and can cause problems in urinating. Many times, the Prostate Gland turns into Prostate Cancer. It is Treated with: Harmotherapy, Radiation Therapy Surgery This Cancer is generally not found in Young People. It is very important to use Chemotherapy and Radiation Therapy. The Detection of DDR Genes. DDR means the Defect of DNA Repair Genes. DDR Genes or Hereditary Prostate Cancers are mostly found in 1-2 % of people. But as our genetic information increased and we became more capable of doing genetic testing, and genetic testing became cheaper, we came to know that DDR genes are found in around 22-25 % of people. Prostate cancer in young men is mostly due to genetic mutations and is very high grade and spreads very fast. Young men's prostate cancer should not be treated like elderly people's prostate cancer. In young men, it is often seen that the amount of PSA, Prostate Specific Antigen, which is a type of blood test, increases very little or does not increase at all. And with PSA monitoring, the increase of cancer can often be missed. It should be monitored not only through PSA but also through: Radiology Assessment. CT scans or PSMA PET CT Scans or in any other way. It is also very important to conduct Gene Testing (DDR Gene Testing) Some new drugs have been introduced in ASIC patients, which we call PARP inhibitors. We Should be Ready to use them and Protect the Next Generation as well.